MedTrace Logo

L-Carnitine Protective Effect in Nephrotoxicity

NCT07108777 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-08-12

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is:

Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?

Conditions

  • Nephrotoxicity

Interventions

DRUG

L-Carnitine Tartrate

L-carnitine 350 mg three times daily by oral.

DRUG

Placebo

placebo tablet three times daily by oral.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Fatma M Eweda, Master · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-10
Primary Completion
2026-08-01
Completion
2026-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07108777 on ClinicalTrials.gov